Maryland State Retirement & Pension System Trims Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Maryland State Retirement & Pension System lowered its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 7.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,340 shares of the company’s stock after selling 370 shares during the period. Maryland State Retirement & Pension System’s holdings in IDEXX Laboratories were worth $1,794,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Geode Capital Management LLC boosted its holdings in IDEXX Laboratories by 1.8% in the third quarter. Geode Capital Management LLC now owns 2,259,537 shares of the company’s stock valued at $1,138,732,000 after purchasing an additional 40,349 shares during the last quarter. Franklin Resources Inc. lifted its holdings in IDEXX Laboratories by 2.5% during the 3rd quarter. Franklin Resources Inc. now owns 1,412,700 shares of the company’s stock worth $675,259,000 after buying an additional 34,305 shares during the last quarter. Amundi lifted its holdings in IDEXX Laboratories by 8.1% during the 4th quarter. Amundi now owns 758,669 shares of the company’s stock worth $328,018,000 after buying an additional 56,837 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in IDEXX Laboratories by 0.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 751,900 shares of the company’s stock worth $379,875,000 after buying an additional 2,463 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in IDEXX Laboratories by 3.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 531,692 shares of the company’s stock worth $219,823,000 after buying an additional 16,213 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insider Activity at IDEXX Laboratories

In related news, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the transaction, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research analysts have commented on the company. StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, March 15th. Leerink Partners assumed coverage on IDEXX Laboratories in a report on Monday, December 2nd. They set an “outperform” rating and a $500.00 target price on the stock. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Piper Sandler raised their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a report on Monday, February 10th. Finally, Barclays raised their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $533.75.

IDEXX Laboratories Stock Up 0.1 %

IDXX opened at $420.99 on Friday. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $548.88. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The stock has a market cap of $34.24 billion, a P/E ratio of 39.46, a P/E/G ratio of 3.41 and a beta of 1.39. The stock’s 50 day moving average price is $437.36 and its 200 day moving average price is $445.11.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.